{
    "root": "301f35b4-d8ad-4a57-e063-6294a90af655",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "levofloxacin",
    "value": "20250312",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "LEVOFLOXACIN",
            "code": "6GNT3Y5LMF"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        }
    ],
    "indications": "levofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) infections caused designated , susceptible bacteria pediatric patients indicated ( 1 , 12.4 ) . pneumonia : nosocomial ( 1.1 ) community acquired ( 1.2 , 1.3 ) skin skin structure infections ( sssi ) : complicated ( 1.4 ) uncomplicated ( 1.5 ) chronic bacterial prostatitis ( 1.6 ) inhalational anthrax , post-exposure adult pediatric patients ( 1.7 ) plague adult pediatric patients ( 1.8 ) urinary tract infections ( uti ) : complicated ( 1.9 , 1.10 ) uncomplicated ( 1.12 ) acute pyelonephritis ( 1.11 ) acute bacterial exacerbation chronic bronchitis ( 1.13 ) acute bacterial sinusitis ( 1.14 ) usage reduce development drug-resistant bacteria maintain effectiveness levofloxacin antibacterial drugs , levofloxacin used treat prevent infections proven strongly suspected caused bacteria ( 1.15 ) .",
    "contraindications": "administer levofloxacin tablets pediatric patients weighing 30 kg greater ( 2.1 , 2.2 ) . levofloxacin tablets administered pediatric patients weigh less 30 kg limitations available strengths . alternative formulations levofloxacin may considered pediatric patients weigh less 30 kg ( 2.2 ) . adult pediatric patients creatinine clearance greater equal 50 ml/minute ( 2.1 , 2.2 ) type infection dose every 24 hours duration ( days ) nosocomial pneumonia ( 1.1 ) 750 mg 7 14 community acquired pneumonia ( 1.2 ) 500 mg 7 14 community acquired pneumonia ( 1.3 ) 750 mg 5 complicated sssi ( 1.4 ) 750 mg 7 14 uncomplicated sssi ( 1.5 ) 500 mg 7 10 chronic bacterial prostatitis ( 1.6 ) 500 mg 28 inhalational anthrax ( post-exposure ) ( 1.7 ) adults pediatric patients 50 kg greater 500 mg 60 pediatric patients 30 kg less 50 kg ( 2.2 ) 250 mg every 12 hours 60 plague ( 1.8 ) adults pediatric patients 50 kg greater 500 mg 10 14 pediatric patients 30 kg less 50 kg ( 2.2 ) 250 mg every 12 hours 10 14 complicated uti ( 1.9 ) acute pyelonephritis ( 1.11 ) 750 mg 5 complicated uti ( 1.10 ) acute pyelonephritis ( 1.11 ) 250 mg 10 uncomplicated uti ( 1.12 ) 250 mg 3 acute bacterial exacerbation chronic bronchitis ( 1.13 ) 500 mg 7 acute bacterial sinusitis ( 1.14 ) 750 mg 5 500 mg 10 14 adjust dose creatinine clearance less 50 ml/minute ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions": "levofloxacin tablets usp , 250 mg white white , modified capsule-shaped , biconvex , film-coated tablets debossed logo 'zc55 ' one side plain side supplied follows : ndc 72578-098-18 bottles 50 tablets child-resistant closures ndc 72578-098-01 bottles 100 tablets child-resistant closures ndc 72578-098-05 bottles 500 tablets levofloxacin tablets usp , 500 mg white white , modified capsule-shaped , biconvex , film-coated tablets debossed logo 'zc56 ' one side plain side supplied follows : ndc 72578-099-18 bottles 50 tablets child-resistant closures ndc 72578-099-01 bottles 100 tablets child-resistant closures ndc 72578-099-05 bottles 500 tablets ndc 72578-099-10 bottles 1,000 tablets levofloxacin tablets usp , 750 mg white white , modified capsule-shaped , biconvex , film-coated tablets debossed logo 'zc57 ' one side plain side supplied follows : ndc 72578-100-92 bottles 20 tablets child-resistant closures ndc 72578-100-06 bottles 30 tablets child-resistant closures ndc 72578-100-18 bottles 50 tablets child-resistant closures ndc 72578-100-01 bottles 100 tablets child-resistant closures ndc 72578-100-05 bottles 500 tablets storage store 20°c 25° c ( 68°f 77° f ) [ usp controlled room temperature ] . dispense well closed container described usp .",
    "adverseReactions": "known hypersensitivity levofloxacin quinolones ( 4 , 5.7 )",
    "indications_original": "Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1 , 12.4 ). Pneumonia: Nosocomial ( 1.1 ) and Community Acquired ( 1.2 , 1.3 ) Skin and Skin Structure Infections (SSSI): Complicated ( 1.4 ) and Uncomplicated ( 1.5 ) Chronic bacterial prostatitis ( 1.6 ) Inhalational Anthrax, Post-Exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Urinary Tract Infections (UTI): Complicated ( 1.9 , 1.10 ) and Uncomplicated ( 1.12 ) Acute Pyelonephritis ( 1.11 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.13 ) Acute Bacterial Sinusitis ( 1.14 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.15 ).",
    "contraindications_original": "Administer levofloxacin tablets to pediatric patients weighing 30 kg and greater only ( 2.1 , 2.2 ). Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg ( 2.2 ). Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute ( 2.1 , 2.2 ) Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia ( 1.1 ) 750 mg 7 to 14 Community Acquired Pneumonia ( 1.2 ) 500 mg 7 to 14 Community Acquired Pneumonia ( 1.3 ) 750 mg 5 Complicated SSSI ( 1.4 ) 750 mg 7 to 14 Uncomplicated SSSI ( 1.5 ) 500 mg 7 to 10 Chronic Bacterial Prostatitis ( 1.6 ) 500 mg 28 Inhalational Anthrax (Post-Exposure) ( 1.7 ) Adults and Pediatric Patients 50 kg or greater 500 mg 60 Pediatric Patients 30 kg to less than 50 kg (2.2) 250 mg every 12 hours 60 Plague ( 1.8 ) Adults and Pediatric Patients 50 kg or greater 500 mg 10 to 14 Pediatric Patients 30 kg to less than 50 kg (2.2) 250 mg every 12 hours 10 to 14 Complicated UTI ( 1.9 ) or Acute Pyelonephritis ( 1.11 ) 750 mg 5 Complicated UTI ( 1.10 ) or Acute Pyelonephritis ( 1.11 ) 250 mg 10 Uncomplicated UTI ( 1.12 ) 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.13 ) 500 mg 7 Acute Bacterial Sinusitis ( 1.14 ) 750 mg 5 500 mg 10 to 14 Adjust dose for creatinine clearance less than 50 mL/minute ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions_original": "Levofloxacin Tablets USP, 250 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC55' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-098-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-098-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-098-05 in bottles of 500 tablets\n                  Levofloxacin Tablets USP, 500 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC56' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-099-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-099-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-099-05 in bottles of 500 tablets\n                  NDC 72578-099-10 in bottles of 1,000 tablets\n                  Levofloxacin Tablets USP, 750 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC57' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-100-92 in bottles of 20 tablets with child-resistant closures\n                  NDC 72578-100-06 in bottles of 30 tablets with child-resistant closures\n                  NDC 72578-100-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-100-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-100-05 in bottles of 500 tablets\n                  \n                     Storage\n                  \n                  Store at 20°C to 25° C (68°F to 77° F) [see USP Controlled Room Temperature]. Dispense in a well closed container as described in the USP.",
    "adverseReactions_original": "Known hypersensitivity to levofloxacin or other quinolones ( 4 , 5.7 )"
}